Harvard Management Company disclosed in its Q1 2026 13F that it fully exited Ethereum exposure by selling the BlackRock iShares Ethereum Trust ETF, a position previously valued at about $87 million at the end of 2025.

HMC also trimmed its stake in BlackRock’s iShares Bitcoin Trust by roughly 43% in Q1 2026, after a 21% cut in the prior quarter, reducing holdings to just over 3 million shares.

In the same period, Harvard reduced exposure to Bitcoin by about 2.3 million shares of Bitcoin ETFs, while maintaining more than 3 million shares of the iShares Bitcoin Trust valued near $117 million.

Analysts note a tension between the Ethereum Foundation’s stated goals and market competition, with some arguing the EF should emphasize tokeneconomics and Ether price appreciation.

Commentators say the EF’s core values—decentralization, privacy, open source, and censorship resistance—remain priority, but concerns persist about tokenomics and ETH’s price competitiveness as rivals push for market share.

Some critics contend the Ethereum Foundation should balance its mandate with strategies to boost Ether’s price, contrasting with calls for more market-driven competition.

Sources for the report include SEC EDGAR filings and media outlets BeInCrypto and Crypto News, with the note that AI assistance informed the article.

Readers should watch Harvard’s next SEC filing and EF leadership updates to determine whether this marks a lasting shift in institutional crypto exposure or a temporary repositioning.

HMC opened a new San Francisco satellite office around 2025–2026 to access West Coast tech and venture opportunities, signaling a strategic focus on technology investments.

The move to reduce Ethereum and related ETF exposure comes about six months after the SEC approved spot Ethereum ETF products alongside Bitcoin ETFs.

Broad exposure remained to semiconductor and tech equities, with Broadcom rising and major positions trimmed in Alphabet, Flutter, and SPDR Gold Shares.

The endowment disclosed a tilt toward growth-oriented AI-biotech via a sizable stake in Generate Biomedicines after purchasing more than 1.1 million shares.